COVID-19: RITM to now evaluate 16 antibody rapid test kits approved by FDA | Inquirer News

COVID-19: RITM to now evaluate 16 antibody rapid test kits approved by FDA

By: - Reporter / @DYGalvezINQ
/ 02:45 PM April 21, 2020

MANILA, Philippines — The Research Institute for Tropical Medicine (RITM) can now evaluate the 16 antibody rapid test kits for the coronavirus disease 2019 (COVID-19) that was earlier approved by the Food and Drug Administration (FDA).

In a statement on Tuesday, FDA said RITM can now assess the test kits “in the interest of national emergency, health, and safety.”

“This is a welcome development, so that the reliability of the kits may be tested on local samples. This will guide end-users in selecting the kits they will use for testing,” FDA Director-General Rolando Domingo said.

ADVERTISEMENT

RITM is supposed to perform the evaluation of the rapid test kits but it earlier did not have the capacity to do this due to the high volume of polymerase chain reaction (PCR) testing and the lack of well-characterized serum samples needed to evaluate the rapid test kits.

FEATURED STORIES

To date, FDA has approved 16 antibody rapid test kits for commercial use. These test kits have already completed the necessary documentary requirements and have undergone review and evaluation.

As part of post-marketing surveillance, the concerned stakeholders of the test kits were directed to submit samples to the RITM laboratory 30 days from receipt of the notice for performance evaluation.

“Recent news from other countries reporting poor performance of rapid antibody tests have cast doubts on the accuracy of some kits,” Domingo said.

“As the Philippines embarks on a mass testing strategy using both PCR based and Rapid Antibody test kits, validation of rapid kits by the RITM would be helpful in choosing the best products to use as we go forward now and after the end of the enhanced community quarantine,” he added.

COVID-19 is a respiratory ailment caused by the novel coronavirus or SARS-CoV-2, which outbreak started in China’s Wuhan City in Hubei province in late 2019.

For most people, the virus causes mild or moderate symptoms, such as fever and cough that clear up in two to three weeks. For some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia, and death.

KGA
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: 2019-nCoV, China, Coronavirus, coronavirus Philippines, COVID-19, DoH, FDA, Health, Local news, Nation, national news, NcoV, nCoV update, News, Outbreak, pandemic, Philippine news updates, RITM, Virus, Wuhan

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.